Legend Biotech Corporation
NASDAQ:LEGNBiotechnology
-$4.53 today
- Market cap
- $3.01B
- Beta
- 0.35
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.35
Volume 2.15M
Average 2.42M
LEGN Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Legend Biotech CorporationNASDAQ: LEGN
Revenue · Q3 FY2026 · quarter ended Sep 2026
Revenue grows, but more slowly than its trailing trend
Q3 FY2026 revenue of $359.5M rose 32.0% year over year, behind the +49.5% change in trailing-twelve-month revenue. Sequentially, it fell 7.2% from the prior quarter. Over 3 fiscal years it compounded at +106.4% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 8 analysts of $1.43B (+39.1%) for the fiscal year ending Dec 2026, a slowdown from the +64.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $359.5M-7.2% QoQ
- Last fiscal yearDec 2025
- $1.03B+64.0% YoY
- LTMSep 2026
- $1.36B+49.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +32.0% | +24.1% | -7.9 pp |
| 1 year | +64.0% | +39.1% | -25.0 pp |
| 3-year CAGR | +106.4% | +22.5% | -83.9 pp |
| 5-year CAGR | +17.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 1.03B USD
- Year-over-year change
- +64.0%
- 4-year CAGR
- +96.6%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.03B | +64.0% |
| FY2024 | 2024-12-31 | 627.24M | +120.0% |
| FY2023 | 2023-12-31 | 285.14M | +143.7% |
| FY2022 | 2022-12-31 | 117.01M | +70.0% |
| FY2021 | 2021-12-31 | 68.83M | — |
Revenue vs competitors
How LEGN compares with its peers on the latest reported figures
- LEGN's LTM Sep 2026 revenue of $1.36B is the highest of the 11 companies compared; the peer median is $8.76M.
- Its year-over-year change of +49.5% is the 2nd highest of 10, against a peer median of -52.3%.
- Over three fiscal years its annual growth of +106.4% compares with a peer median of +10.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $1.36B | +49.5% | +106.4% | |
| LTM Mar 2026 | $92.59M | +927.5% | +130.2% | |
| LTM Mar 2026 | $68.09M | +42.9% | +56.1% | |
| LTM Mar 2026 | $45.07M | -11.9% | +10.9% | |
| LTM Mar 2026 | $23.14M | -88.4% | +23.9% | |
| LTM Mar 2026 | $11.2M | +13.0% | -7.0% | |
| LTM Mar 2026 | $6.32M | -52.6% | -59.0% | |
| LTM Mar 2026 | $1.78M | -94.8% | -70.7% | |
| LTM Mar 2026 | $31K | -52.3% | -92.5% | |
| LTM Mar 2026 | $0 | -100.0% | +175.9% | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding LEGN) | $8.76M | -52.3% | +10.9% | |
Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 68.83M | 117.01M | 285.14M | 627.24M | 1.03B |
| Cost of Revenue | 0 | 65.36M | 144.21M | 234.58M | 408.1M |
| Gross Profit | 68.83M | 51.64M | 140.93M | 392.66M | 620.8M |
| Gross Margin | 100.0% | 44.1% | 49.4% | 62.6% | 60.3% |
| Research & Development | 313.35M | 335.65M | 382.22M | 413.54M | 414.7M |
| Selling, General & Admin | 149.5M | 174.05M | 200.93M | 284.26M | 341.6M |
| Operating Expenses | 461.11M | 507.26M | 580.41M | 695.9M | 757.3M |
| Depreciation & Amortization | 13.92M | 18.39M | 20.45M | 23.36M | 28.9M |
| EBITDA | (392.38M) | (416.54M) | (477.87M) | (113.16M) | (232.3M) |
| EBITDA Margin | -570.1% | -356.0% | -167.6% | -18.0% | -22.6% |
| Operating Income | (392.29M) | (455.62M) | (439.49M) | (303.24M) | (136.5M) |
| Operating Margin | -570.0% | -389.4% | -154.1% | -48.3% | -13.3% |
| Interest Income | 971K | 8.18M | 54.49M | 61.2M | 40.1M |
| Interest Expense | 900K | 10.8M | 21.79M | 21.62M | 21.4M |
| Other Income / Expenses | (14.91M) | 9.9M | (80.63M) | 145.11M | (146.1M) |
| Income Before Tax | (407.2M) | (445.72M) | (520.12M) | (158.13M) | (282.6M) |
| Pre-Tax Margin | -591.6% | -380.9% | -182.4% | -25.2% | -27.5% |
| Income Tax Expense | (3.61M) | 625K | (1.86M) | 18.89M | 14.2M |
| Net Income | (403.58M) | (446.35M) | (518.25M) | (177.03M) | (296.8M) |
| Net Margin | -586.4% | -381.5% | -181.8% | -28.2% | -28.8% |
| EPS (Basic) | (2.74) | (2.81) | (2.94) | (0.97) | (1.60) |
| EPS (Diluted) | (2.74) | (2.81) | (2.94) | (0.97) | (1.60) |
| Weighted Avg Shares | 140.85M | 159.04M | 176.08M | 182.85M | 184.32M |
| Weighted Avg Shares (Diluted) | 140.85M | 159.04M | 176.08M | 182.85M | 184.32M |
Legend Biotech Corporation
NASDAQ:LEGN
Intrinsic Alpha fair value
Locked
Current Price
$16.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.